Inventiva (NASDAQ:IVA) Shares Gap Down – Should You Sell?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped down prior to trading on Wednesday . The stock had previously closed at $3.97, but opened at $3.74. Inventiva shares last traded at $3.8510, with a volume of 95,913 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on IVA shares. Truist Financial started coverage on Inventiva in a research report on Thursday, March 19th. They issued a “buy” rating and a $13.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Finally, Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Inventiva has an average rating of “Buy” and a consensus price target of $16.56.

Inventiva Stock Performance

The business has a 50 day moving average of $5.10 and a 200-day moving average of $5.40.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million during the quarter. As a group, analysts expect that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Creative Planning purchased a new position in Inventiva during the 2nd quarter worth approximately $32,000. Virtu Financial LLC purchased a new position in Inventiva during the 4th quarter worth approximately $60,000. XTX Topco Ltd purchased a new position in Inventiva during the 4th quarter worth approximately $84,000. NewEdge Advisors LLC purchased a new position in Inventiva during the 3rd quarter worth approximately $116,000. Finally, Cerity Partners LLC purchased a new position in Inventiva during the 4th quarter worth approximately $93,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.